Cargando…

The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?

RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokrivcak, Tomas, Lakomy, Radek, Kazda, Tomas, Poprach, Alexandr, Fabian, Pavel, Kiss, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213256/
https://www.ncbi.nlm.nih.gov/pubmed/34128899
http://dx.doi.org/10.1097/MD.0000000000026381
_version_ 1783709806267203584
author Pokrivcak, Tomas
Lakomy, Radek
Kazda, Tomas
Poprach, Alexandr
Fabian, Pavel
Kiss, Igor
author_facet Pokrivcak, Tomas
Lakomy, Radek
Kazda, Tomas
Poprach, Alexandr
Fabian, Pavel
Kiss, Igor
author_sort Pokrivcak, Tomas
collection PubMed
description RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant.
format Online
Article
Text
id pubmed-8213256
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-82132562021-06-21 The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors? Pokrivcak, Tomas Lakomy, Radek Kazda, Tomas Poprach, Alexandr Fabian, Pavel Kiss, Igor Medicine (Baltimore) 5700 RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant. Lippincott Williams & Wilkins 2021-06-18 /pmc/articles/PMC8213256/ /pubmed/34128899 http://dx.doi.org/10.1097/MD.0000000000026381 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5700
Pokrivcak, Tomas
Lakomy, Radek
Kazda, Tomas
Poprach, Alexandr
Fabian, Pavel
Kiss, Igor
The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title_full The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title_fullStr The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title_full_unstemmed The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title_short The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
title_sort use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213256/
https://www.ncbi.nlm.nih.gov/pubmed/34128899
http://dx.doi.org/10.1097/MD.0000000000026381
work_keys_str_mv AT pokrivcaktomas theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT lakomyradek theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT kazdatomas theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT poprachalexandr theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT fabianpavel theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT kissigor theuseofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT pokrivcaktomas useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT lakomyradek useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT kazdatomas useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT poprachalexandr useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT fabianpavel useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors
AT kissigor useofcisplatininpatientsafterkidneytransplantationwithchronicrenalinsufficiencyisthebenefithigherthanpotentialrisksintherapyofnonseminomatousgermcelltumors